High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2: A prospective study

Intervirology

Volumn 47, Issue 6, 2004, Pages 328-334

  Yokosuka, Osamu ^a   Iwama, Shosuke ^b   Suzuki, Noriaki ^c   Takashi, Motohide ^d   Hirai, Yasuo ^e   Uchiumi, Katsuo ^f   Kimura, Michio ^g   Gotou, Nobuaki ^h   Hino, Shinichi ^d   Hayasaka, Akira ^c   Kanda, Tatsuo ^a   Kawai, Shigenobu ^a   Fukai, Kenichi ^a   Imazeki, Fumio ^a   Saisho, Hiromitsu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA ROSAI HOSPITAL   (Japan)

^c KIMITSU CHUO HOSPITAL   (Japan)

^d Saiseikai Narashino Hospital   (Japan)

^e Matsudo City Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

^g Chiba Kaihin Municipal Hospital   (Japan)

^h Numazu City Hospital   (Japan)

Author keywords

Genotype; Hepatitis C; Hepatitis C virus RNA; Interferon; Ribavirin; Sustained virologic response

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; PRIORITY JOURNAL; RASH; RETINA HEMORRHAGE; TREATMENT OUTCOME; VIRUS TITRATION;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 9144260228     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080876     Document Type: Article

References (30)

1. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, Ogura K, Niwa Y, Kawabe T, Omata M: Characteristic difference of hepatocellular carcinoma between hepatitis B and C viral infection in Japan. Hepatology 1995;22:1027-1033.
2. Yokosuka O, Kojima H, Imazeki F, Tagawa M, Saisho H, Tamatsukuri S, Omata M: Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: Analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999;31:394-399.
3. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. New Engl J Med 1986;315:1575-1578.
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tambarro C, Lefkowich J, Albrechit J, Meschievitz C, Ortego TJ, Bigas A, The Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-1506.
5. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
6. Shindo M, Di Bisceglie AM, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-1016.
7. Yokosuka O, Kato N, Hosoda K, Ito Y, Imazeki F, Ohto M, Omata M: Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for chronic hepatitis C virus RNA. Gut 1995;37; 721-726.
8. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program in Japan of cirrhotic and non-cirrhotic patients with chronic hepatitis C. Ann Intern Med 1999;131; 174-181.
9. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K, The Osaka Liver Disease Study Group: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.
10. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-789.
11. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
12. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-1354.
13. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
14. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
15. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, Mayumi M: Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
16. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S: A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994;89:2151-2156.
17. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-299.
18. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Kumada H: Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
19. Kawai S, Yokosuka O, Imazeki F, Saisho H, Mizuno C: Evaluation of the clinical usefulness of COBAS Amplicor HCV monitor assay (ver 2.0): Comparison with Amplicor HCV monitor assay (ver 1.0) and HCV core protein level. J Med Virol 2002;68:343-351.
20. McHuchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa 2b alone or in combination with ribavirin for the treatment for chronic hepatitis C. N Engl J Med 1998;339; 1485-1492.
21. Davis GL, Esteban-Mur R, Rustigi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J: Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339; 1493-1499.
22. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O: Randomized, double-blind, placebo-controlled trial of interferon-alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351; 83-87.
23. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-2432.
24. Poynard T, McHutchson J, Goodman Z, Ling MH, Albrecht J: Is a 'A la Carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000;31; 211-218.
25. Young KKY, Resnick RM, Meyers TW: Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993;31:882-886.
26. Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, Mizokami M, Ohba K, Tanaka S, Hattori N, Nomoto A, Kohara M: Antigenicities of group I and II hepatitis virus polypeptides-molecular basis of diagnosis. Virology 1993;192:430-437.
27. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M: Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-1353.
28. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC: Sequence variability in the 5′ non-coding region of hepatitis C virus. J General Virol 1993;74:661-668.
29. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus by polymerase chain reaction with type specific primers: Application to clinical surveys and tracing infectious sources. J General Virol 1992;73:673-679.
30. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.